Arguments evaluation (drug licensing and local trials): Should all drugs patented and manufactured in Western countries be tried on a sample basis in India before licensing for sale to the public? Evaluate—(I) Yes: dosage and duration may differ for the Indian population, making local evaluation necessary; (II) No: it is not feasible to implement—determine which argument(s) are strong.

Given data

• Policy under consideration: Local sample trials before licensing foreign-patented drugs.
• Argument I: Necessary due to possible population-specific differences in dose/response.
• Argument II: Not feasible, hence cannot be implemented.

Concept / Approach
Public-health safety and pharmacovigilance support context-specific evaluation. Feasibility objections, without evidence or alternatives, are not strong by themselves.

Step-by-step evaluation
Step 1: I appeals to clinical relevance (ethnicity, environment, comorbidities) and is logically strong.Step 2: II asserts infeasibility but provides no substantive reason or mitigation; it is weak as a basis to deny a safety measure.

Verification / Alternative
Regulatory norms often require bridging studies or Phase IV surveillance—consistent with argument I.

Common pitfalls

• Letting administrative convenience override patient safety in principle-level questions.

Final Answer
Only argument I is strong.